Published on: Wednesday, 10 September 2025 ● 3 Min Read
SCOTTSDALE, Ariz., Sept. 10, 2025 -- Imaging Endpoints (IE), the global leader in Imaging CRO technologies and services for oncology trials, announced the filing of a provisional patent application for its revolutionary AI enhanced Imaging Review Charter (IRC) system. This innovative AIRC System™ is designed to enhance highly customized IRCs for clinical trials, setting new standards in the industry.
Imaging Endpoints is the scientific leader in customizing and optimizing image acquisition and analysis for clinical trials in oncology, with the most sophisticated approach in the industry for ensuring clarification(s) and/or modification(s) of published criteria to enhance each unique clinical trial design. This advanced approach to image analysis has contributed to the Company's remarkable 95% marketing approval success rate across over 200 regulatory approvals supported.
The new AIRC System addresses long-standing challenges in trial imaging design by assisting in the assimilation of data for intelligent, tailored modifications and/or clarifications to standard oncology criteria while ensuring alignment to current regulatory requirements of the FDA, EMA and other regulatory agencies across the globe.
Key Features of the New AIRC System:
Doug Dean Burkett, CEO and President of Imaging Endpoints, commented on the innovation: "For over fifteen years, IE has been at the forefront of imaging CRO services within oncology. The filing of this patent marks another milestone in our commitment to Connect Imaging to the Cure™. This AI enhanced IRC System enhances the efficiency and effectiveness of oncology trials while further solidifying our industry leadership."
For more information, or a copy of Imaging Endpoint's recent white paper on criteria optimization, see Optimizing Imaging Response Criteria for Improved Outcomes in Oncology Clinical Trials
About Imaging Endpoints
Imaging Endpoints (IE) is passionately focused on its vision to Connect Imaging to the Cure. With a flawless global inspection record and a remarkable 95% marketing authorization success rate, IE has a proven track record of supporting successful regulatory submissions across the globe. IE's commitment to quality, innovation, rapid turnaround times, and operational excellence has positioned it as the global leader in oncology imaging.
Imaging Endpoints is the largest oncology Imaging CRO, with 8 offices strategically located across 6 countries including Scottsdale, AZ, Cambridge, MA; London, UK; Leiden, Netherlands; Basel, Switzerland; Hyderabad, India; and Shanghai, China.
IE is an affiliate of HonorHealth, one of the largest healthcare systems nationally, and Southwest Medical Imaging, Ltd. (SMIL/RadPartners), part of the largest private radiology group in the U.S.
For further media queries, please contact: IE.MediaRelations@imagingendpoints.com | Contact no. +1 480.314.3070.
Photo: https://mma.prnewswire.com/media/2769856/Imaging_Endpoints_patent_AIRC.jpg
Logo: https://mma.prnewswire.com/media/2405461/4689168/Imaging_Endpoints_Logo.jpg
No comments posted
© 2019 KIVAA Group | All right reserved. www.theindustrial.in
Leave a reply: